Bionano Genomics, Inc.
BNGO
$4.10
$0.102.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.16M | 6.07M | 7.77M | 8.77M | 10.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.16M | 6.07M | 7.77M | 8.77M | 10.72M |
| Cost of Revenue | 4.75M | 14.52M | 5.19M | 5.95M | 8.28M |
| Gross Profit | 3.42M | -8.45M | 2.59M | 2.82M | 2.44M |
| SG&A Expenses | 856.00K | 9.46M | 11.56M | 19.73M | 18.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.08M | 28.70M | 23.57M | 35.45M | 38.92M |
| Operating Income | -913.00K | -22.63M | -15.80M | -26.68M | -28.20M |
| Income Before Tax | -20.12M | -44.22M | -16.20M | -31.44M | -43.93M |
| Income Tax Expenses | 1.00K | 24.00K | 26.00K | -18.00K | -36.00K |
| Earnings from Continuing Operations | -20.13M | -44.25M | -16.22M | -31.42M | -43.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.13M | -44.25M | -16.22M | -31.42M | -43.89M |
| EBIT | -913.00K | -22.63M | -15.80M | -26.68M | -28.20M |
| EBITDA | 1.33M | -16.95M | -12.76M | -23.63M | -24.76M |
| EPS Basic | -12.22 | -30.92 | -14.40 | -35.75 | -66.13 |
| Normalized Basic EPS | -2.17 | -10.02 | -10.51 | -19.20 | -44.43 |
| EPS Diluted | -12.22 | -30.92 | -14.40 | -36.00 | -66.13 |
| Normalized Diluted EPS | -2.17 | -10.02 | -10.51 | -19.20 | -44.43 |
| Average Basic Shares Outstanding | 1.65M | 1.43M | 1.13M | 879.00K | 663.70K |
| Average Diluted Shares Outstanding | 1.65M | 1.43M | 1.13M | 879.00K | 663.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |